

## **Devyser enters Strategic Supply Agreement with Illumina to offer sequencing instruments and products**

**Devyser today announced that it entered a strategic agreement with Illumina, a global leader in DNA sequencing and array-based technologies, to provide Illumina sequencing instruments and related products to Devyser customers.**

Under the agreement, Devyser will be able to offer selected Illumina sequencing instruments together with Devyser's reagent solutions, enabling customers to access advanced sequencing technology with reduced upfront capital investment. The framework is designed to simplify procurement, accelerate implementation, and support laboratories in expanding their testing capabilities.

"This agreement strengthens our ability to deliver complete, scalable solutions to our customers," said Theis Kipling, Chief Commercial Officer at Devyser. "By combining Illumina's industry-leading sequencing platforms with Devyser's validated genetic testing assays, we can lower barriers to adoption and help laboratories more quickly implement high-quality genetic testing."

The model allows Devyser customers to access sequencing instruments through an ongoing reagent commitment rather than a traditional purchase model. This approach is particularly attractive for clinical laboratories seeking predictable costs, faster onboarding, and flexibility as testing volumes grow.

Illumina's sequencing platforms are widely used in clinical and research settings worldwide. The agreement complements Devyser's strategy to provide end-to-end testing solutions that support laboratories across clinical genetics and transplant diagnostics.

"This agreement underscores Illumina's focus on making next-generation sequencing more accessible and easier to implement," said Bas Verhoef, SVP and Head of Region, EMEA & Latin America, Illumina. "Partnering with Devyser will simplify workflows and support customers in delivering high-quality, scalable solutions for testing."

### **For more information, please contact:**

Jan Wahlström, CEO

E-mail: [ir@devyser.com](mailto:ir@devyser.com)

Telephone: +46 8 562 158 50

Theis Kipling, CCO

E-mail: [ir@devyser.com](mailto:ir@devyser.com)

Telephone: +46 8 562 158 50



**PRESS RELEASE**

28 January 2026 10:00:00 CET

**About Devyser**

Devyser is redefining how laboratories approach genetic testing. As your true one-stop shop, we offer streamlined solutions for a wide range of conditions, helping labs overcome complexity, reduce turnaround times, and maximize efficiency.

Our technologies simplify workflows, minimize hands-on time, and deliver fast, accurate results. Every test is designed to empower labs to do more with less, freeing up resources while supporting better patient outcomes.

We specialize in diagnostic kits and advanced analysis services for clinical genetics and post-transplantation laboratories - two critical areas where accuracy and speed matter. With customers in 65+ countries, we also operate our own CLIA-certified laboratory, Devyser Genomic Laboratories, in Atlanta and maintain sales offices across Europe and the US.

Devyser is committed to regulatory excellence under IVDR, ensuring the highest quality standards across our growing product portfolio.

Founded in 2004 and headquartered in Stockholm, Devyser is listed on the Nasdaq First North Premier Growth Market Stockholm (ticker: DVYSR). The company's Certified Adviser is Redeye AB.

Discover how we're shaping the future of lab diagnostics at [www.devyser.com](https://www.devyser.com).